Related Experiment Video

Updated: Feb 22, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.5K

Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches

John H Strickler1, Christina Wu2, Tanios Bekaii-Saab3

  • 1Duke University School of Medicine, 20 Duke Medicine Circle, Durham, NC 27710, USA.

Cancer Treatment Reviews
|September 26, 2017
PubMed

Insights

BRAF-mutant metastatic colorectal cancer (mCRC) has a poor prognosis and limited treatment options. This review covers BRAF-mutant CRC

Area of Science:

  • Oncology
  • Gastroenterology
  • Molecular Biology

Background:

  • BRAF mutations are found in 7-10% of metastatic colorectal cancers (mCRC).
  • BRAF-mutant mCRC patients exhibit poor response to standard therapies and have a dismal prognosis.
  • A significant unmet need exists for effective treatments for BRAF-mutant mCRC.

Purpose of the Study:

  • To review the epidemiology, molecular pathology, prognosis, and treatment resistance mechanisms of BRAF-mutated CRC.
  • To highlight emerging therapeutic strategies for BRAF-mutant CRC.

Main Methods:

  • Literature review of epidemiological data.
  • Analysis of molecular pathogenesis and resistance mechanisms.
  • Synthesis of current and novel therapeutic approaches.

Main Results:

  • BRAF mutations significantly impact CRC progression and treatment outcomes.
  • Understanding resistance mechanisms is key to developing new therapies.
  • Several novel therapeutic strategies show promise for improving patient response.

Conclusions:

  • BRAF-mutant CRC presents unique challenges requiring targeted therapeutic strategies.
  • Further research into novel treatments is crucial for improving outcomes in this patient population.
Keywords:
BRAFColorectal cancerTargeted therapy

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.5K
A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
30